Aldafermin Completed Phase 1 Trials for Impaired Hepatic Function Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT04823702Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function